Open AccessThe prognostic impact of K-RAS mutations in adult acute myeloid leukemia patients treated with high-dose cytarabine
Author(s) -
Ebtesam I Ahmad,
Heba H. Gawish,
Nashwa M. Al Azizi,
Ashraf M Elhefni
Publication year - 2011
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s12602
Subject(s) - cytarabine , medicine , myeloid leukemia , gastroenterology , leukemia , chemotherapy , oncology
Activating point mutation of the RAS gene has been generally accepted as an oncogenic event in a variety of malignancies. It represents one of the most common genetic alterations in acute myeloid leukemia (AML). However, little is known about its clinical relevance in the treatment outcome for this leukemia.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom